ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Michael Gordon of Fenway still part of PMN?

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Feb 09, 2022 4:35pm

106 Views

Post# 34414245

RE:RE:RE:RE:RE:RE:RE:RE:Michael Gordon of Fenway still part of PMN?

Mole, I wouldn't be surprised if PMN is indeed behind this Account but it may lead to more trouble and legal issues if they start responding to each and everyone here. M101 might be sued to the bone and it's a good thing Retiredcop has limited his Posts to only slightly Pumping as his last Post was in regards to the SP going up with no real reason. It's probably a good thing we have a bunch of crazies here to atleast have PMN chip in time to time.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario